HealthTech Arkansas and SymBiosis have come together to create BioAR Trial, an accelerator program to help biotherapeutics companies in late pre-clinical stages of development bring groundbreaking therapies to market faster, while increasing Arkansans’ access to cutting-edge clinical care and innovative medicines.
Companies from around the world are invited to apply to participate in BioAR Trial, which will focus on deploying advanced and emerging therapeutic modalities—such as precision medicines, biologics, cell therapies, and genetic medicines—to treat serious and life-threatening diseases in oncology, immune disorders, and cardio-metabolic disease. The application for BioAR Trial is now open through January 15, 2022, at bioarkansas.co. BioAR Trial’s first cohort of five companies will begin in April 2023.
BioAR Trial’s partner hospitals and health systems are:
Arkansas Children’s Research Institute
Arkansas Heart Hospital
Baptist Health
CHI St. Vincent
Highlands Oncology Group
St. Bernards Healthcare
University of Arkansas for Medical Sciences
More information can be found at bioarkansas.co.